Cargando…
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKAC...
Autores principales: | Bauer, Jens, Köhler, Natalie, Maringer, Yacine, Bucher, Philip, Bilich, Tatjana, Zwick, Melissa, Dicks, Severin, Nelde, Annika, Dubbelaar, Marissa, Scheid, Jonas, Wacker, Marcel, Heitmann, Jonas S., Schroeder, Sarah, Rieth, Jonas, Denk, Monika, Richter, Marion, Klein, Reinhild, Bonzheim, Irina, Luibrand, Julia, Holzer, Ursula, Ebinger, Martin, Brecht, Ines B., Bitzer, Michael, Boerries, Melanie, Feucht, Judith, Salih, Helmut R., Rammensee, Hans-Georg, Hailfinger, Stephan, Walz, Juliane S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613889/ https://www.ncbi.nlm.nih.gov/pubmed/36302754 http://dx.doi.org/10.1038/s41467-022-33746-3 |
Ejemplares similares
-
Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA
por: Neumayer, Christoph, et al.
Publicado: (2023) -
Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma
por: Tomasini, Michael D., et al.
Publicado: (2018) -
DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma
por: Vyas, Monika, et al.
Publicado: (2019) -
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
por: Bilich, Tatjana, et al.
Publicado: (2021) -
Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
por: Tegeler, Christian M., et al.
Publicado: (2022)